Cargando…

Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies

Odronextamab is a fully‐human IgG4‐based CD20xCD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering T‐cell‐mediated cytotoxicity independent of T‐cell‐receptor recognition. Adequate safety, tolerability, and encouraging durable complete responses have been observed in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Min, Olson, Kara, Kirshner, Jessica R., Khaksar Toroghi, Masood, Yan, Hong, Haber, Lauric, Meagher, Craig, Flink, Dina M., Ambati, Srikanth R., Davis, John D., DiCioccio, A. Thomas, Smith, Eric J., Retter, Marc W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010254/ https://www.ncbi.nlm.nih.gov/pubmed/34997701 http://dx.doi.org/10.1111/cts.13212

Ejemplares similares

PB2343: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS STANDARD OF CARE THERAPY IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (OLYMPIA-4)
por: Hawkes, Eliza A., et al.
Publicado: (2023)

PB2266: TRIAL IN PROGRESS: PHASE 3 TRIAL OF ODRONEXTAMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5)
por: Vitolo, Umberto, et al.
Publicado: (2023)

A drug‐disease model for predicting survival in an Ebola outbreak
por: Toroghi, Masood Khaksar, et al.
Publicado: (2022)

Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy
por: Weinstock, Matt, et al.
Publicado: (2022)

PB2279: TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) – A COHORT FROM THE ELM-2 STUDY
por: Cho, Seok-Goo, et al.
Publicado: (2023)

PB2267: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)
por: Luminari, Stefano, et al.
Publicado: (2023)

PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
por: Novelli, Silvana, et al.
Publicado: (2023)

P1115: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
por: Walewski, Jan, et al.
Publicado: (2023)

PB2335: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHOP (O-CHOP) VERSUS R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (OLYMPIA-3)
por: Tessoulin, Benoit, et al.
Publicado: (2023)

P1083: ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2
por: Taszner, Michał, et al.
Publicado: (2023)

Preclinical PET imaging with the novel human antibody (89)Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues
por: Kelly, Marcus P, et al.
Publicado: (2021)

A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab
por: Khaksar Toroghi, Masood, et al.
Publicado: (2021)

Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL‐4Rα, in Atopic Dermatitis Patients and Normal Volunteers
por: Kovalenko, P, et al.
Publicado: (2016)

Novel genetic variants in miR-191 gene and familial ovarian cancer
por: Shen, Jie, et al.
Publicado: (2010)

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
por: Smith, Eric J., et al.
Publicado: (2015)

PB2366: TRIAL IN PROGRESS: PHASE 1 TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF ODRONEXTAMAB IN COMBINATION WITH CEMIPLIMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Segura, Cecilia Carmen Carpio, et al.
Publicado: (2023)

Population Pharmacokinetic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using a Michaelis–Menten Approximation of a Target-Mediated Drug Disposition Model—Support for a Biologics License Application Submission: Part I
por: Martinez, Jean-Marie, et al.
Publicado: (2018)

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies
por: Yang, Feng, et al.
Publicado: (2021)

A counterpoint to “training the translational workforce: expanding beyond translational research to include translational science”
por: Marantz, Paul R., et al.
Publicado: (2020)

High Affinity Antigen Recognition of the Dual Specific Variants of Herceptin Is Entropy-Driven in Spite of Structural Plasticity
por: Bostrom, Jenny, et al.
Publicado: (2011)

Aberrations of TACC1 and TACC3 are associated with ovarian cancer
por: Lauffart, Brenda, et al.
Publicado: (2005)

Adiposity Predicts Cognitive Decline in Older Persons with Diabetes: A 2-Year Follow-Up
por: Abbatecola, Angela Marie, et al.
Publicado: (2010)

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data
por: Kovalenko, Pavel, et al.
Publicado: (2021)

PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Mutsaers, Pim G. N. J., et al.
Publicado: (2023)

Is translational research compatible with preclinical publication strategies?
por: Linder, Stig, et al.
Publicado: (2006)

Lost in translation? Bridging the preclinical / clinical divide
por: Baker, Mark, et al.
Publicado: (2012)

Translating genetic and preclinical findings into autism therapies
por: Chahrour, Maria, et al.
Publicado: (2017)

Preclinical Studies and Translational Applications of Intracerebral Hemorrhage
por: Siaw-Debrah, Felix, et al.
Publicado: (2017)

Preclinical Models: Boosting Synergies for Improved Translation
por: Attanasio, Chiara, et al.
Publicado: (2020)

Certification of clinical and translational researchers: An ill-conceived notion
por: Marantz, Paul R., et al.
Publicado: (2017)

Aiming for a bull’s-eye: Targeting antifungals to fungi with dectin-decorated liposomes
por: Meagher, Richard B., et al.
Publicado: (2021)

Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology
por: Zhu, Andy ZX
Publicado: (2018)

Complex Segregation Analysis of Pedigrees from the Gilda Radner Familial Ovarian Cancer Registry Reveals Evidence for Mendelian Dominant Inheritance
por: Tayo, Bamidele O., et al.
Publicado: (2009)

Evaluation of Potential Disease‐Mediated Drug–Drug Interaction in Patients With Moderate‐to‐Severe Atopic Dermatitis Receiving Dupilumab
por: Davis, John D., et al.
Publicado: (2018)

Successful clinical translation of preclinical combinations of radiation and immunotherapy
por: Formenti, Silvia C., et al.
Publicado: (2013)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

Preclinical to clinical translation of anti-PD-1 blockade
por: Hirsch, Heather, et al.
Publicado: (2015)

Translational Animal Models of Atopic Dermatitis for Preclinical Studies  
por: Martel, Britta C., et al.
Publicado: (2017)

Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics
por: Dong, Shujun, et al.
Publicado: (2022)

BAP editorial: Improving the validity and translation of preclinical research
por: Pratt, Judith A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hsi0u5jrck4qgq0ufgrd6l18ps